Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price hit a new 52-week high on Tuesday . The stock traded as high as $64.85 and last traded at $64.70, with a volume of 126643 shares trading hands. The stock had previously closed at $64.22.
Gemini Therapeutics Stock Performance
The company has a 50 day moving average of $54.03 and a two-hundred day moving average of $47.49. The stock has a market cap of $2.80 billion, a PE ratio of -64.22 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- Insider Trades May Not Tell You What You Think
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- 3 Stocks to Consider Buying in October
- Netflix Is On Track To Hit $1,000 By Christmas
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
